Rijul S Kshirsagar, Jacob G Eide, Jacob Harris, Arash Abiri, Daniel M Beswick, Eugene H Chang, Nicholas Fung, Michelle Hong, Brian J Johnson, Michael A Kohanski, Christopher H Le, Jivianne T Lee, Seyed A Nabavizadeh, Isaac P Obermeyer, Vivek C Pandrangi, Carlos D Pinheiro-Neto, Timothy L Smith, Carl H Snyderman, Jeffrey D Suh, Eric W Wang, Marilene B Wang, Garret Choby, Mathew Geltzeiler, Jillian Lazor, Tara C Mitchell, Edward C Kuan, James N Palmer, Nithin D Adappa
{"title":"鼻黏膜黑色素瘤的免疫治疗效果。","authors":"Rijul S Kshirsagar, Jacob G Eide, Jacob Harris, Arash Abiri, Daniel M Beswick, Eugene H Chang, Nicholas Fung, Michelle Hong, Brian J Johnson, Michael A Kohanski, Christopher H Le, Jivianne T Lee, Seyed A Nabavizadeh, Isaac P Obermeyer, Vivek C Pandrangi, Carlos D Pinheiro-Neto, Timothy L Smith, Carl H Snyderman, Jeffrey D Suh, Eric W Wang, Marilene B Wang, Garret Choby, Mathew Geltzeiler, Jillian Lazor, Tara C Mitchell, Edward C Kuan, James N Palmer, Nithin D Adappa","doi":"10.1177/19458924241308953","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.</p><p><strong>Objective: </strong>We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.</p><p><strong>Methods: </strong>A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.</p><p><strong>Results: </strong>52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (<i>n</i> = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (<i>n</i> = 17, 32.7%) or pembrolizumab (<i>n</i> = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.</p><p><strong>Conclusion: </strong>Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"102-108"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.\",\"authors\":\"Rijul S Kshirsagar, Jacob G Eide, Jacob Harris, Arash Abiri, Daniel M Beswick, Eugene H Chang, Nicholas Fung, Michelle Hong, Brian J Johnson, Michael A Kohanski, Christopher H Le, Jivianne T Lee, Seyed A Nabavizadeh, Isaac P Obermeyer, Vivek C Pandrangi, Carlos D Pinheiro-Neto, Timothy L Smith, Carl H Snyderman, Jeffrey D Suh, Eric W Wang, Marilene B Wang, Garret Choby, Mathew Geltzeiler, Jillian Lazor, Tara C Mitchell, Edward C Kuan, James N Palmer, Nithin D Adappa\",\"doi\":\"10.1177/19458924241308953\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.</p><p><strong>Objective: </strong>We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.</p><p><strong>Methods: </strong>A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.</p><p><strong>Results: </strong>52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (<i>n</i> = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (<i>n</i> = 17, 32.7%) or pembrolizumab (<i>n</i> = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.</p><p><strong>Conclusion: </strong>Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.</p>\",\"PeriodicalId\":7650,\"journal\":{\"name\":\"American Journal of Rhinology & Allergy\",\"volume\":\" \",\"pages\":\"102-108\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Rhinology & Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/19458924241308953\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Rhinology & Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/19458924241308953","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.
Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.
Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.
Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.
Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.
Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.
期刊介绍：
The American Journal of Rhinology & Allergy is a peer-reviewed, scientific publication committed to expanding knowledge and publishing the best clinical and basic research within the fields of Rhinology & Allergy. Its focus is to publish information which contributes to improved quality of care for patients with nasal and sinus disorders. Its primary readership consists of otolaryngologists, allergists, and plastic surgeons. Published material includes peer-reviewed original research, clinical trials, and review articles.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
